Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...

Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

We will release our first-quarter 2025 results on Wednesday, April 23, 2025, and webcast a conference call to discuss results. Key Takeaways: AT&T will release its first-quarter 2025 results on April ...

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024Entered into asset purchase agreement ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Once given final approval by the European Commission, Takeda will market the drug in the EU following an agreement with Tigenix signed last year. In the likely event of an EU licence for the ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, ...

Comparative assessments and other editorial opinions are those of U.S. News and have not been previously reviewed, approved ...

Europe should reduce its dependence on a small number of countries for vital drug supplies such as antibiotics and ...

European Health Commissioner Oliver Varhelyi and Commission Executive Vice President Teresa Ribera said Tuesday during a conference in Strasbourg that the plan--named Critical Medicines Act--aims to ...